June 2012, Year IV, n. 6
Guido Rasi
Dialogue on pharmaceutical innovation will bear fruit
Telos: You were the Director of the Italian Medicines Agency (AIFA) throughout most of the economic crisis so far, during times when tough negotiations occurred between the different levels of Government dealing with the management of public healthcare spending. How has this climate affected AIFA?
Guido Rasi: When I took office in 2008, AIFA was a recently-established agency with great potential but facing several critical issues from both the organisational and structural point of view: this led to a huge amount of outstanding files. We deemed it necessary to draw up a new Regulation of the Agency, which was approved in 2009 and has completely reshaped its structure, allowing it to meet its efficiency and effectiveness targets... more
Editorial
We are today facing the paradox of unprecedented progress in medical science, whilst at the same time seeing the universality of pharmaceutical assistance threatened by the costs of innovation. Striking a balance between the needs of the parties involved in this standoff is not easy: to remunerate the industry’s investment in research and development ... more
SocialTelos